We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma.
- Authors
Alderuccio, Juan Pablo; Desai, Amrita; Yepes, Monica M.; Chapman, Jennifer R.; Vega, Francisco; Lossos, Izidore S.
- Abstract
Key Clinical Message: We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.
- Subjects
BREAST implants; LYMPHOMAS; BREAST cancer; DUCTAL carcinoma; CYCLOPHOSPHAMIDE
- Publication
Clinical Case Reports, 2018, Vol 6, Issue 4, p634
- ISSN
2050-0904
- Publication type
Case Study
- DOI
10.1002/ccr3.1382